Xencor/$XNCR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Xencor
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Ticker
$XNCR
Sector
Primary listing
Employees
250
Headquarters
Website
Xencor Metrics
BasicAdvanced
$993M
-
-$1.77
0.98
-
Price and volume
Market cap
$993M
Beta
0.98
52-week high
$26.42
52-week low
$6.92
Average daily volume
1.3M
Financial strength
Current ratio
5.995
Quick ratio
5.699
Long term debt to equity
24.485
Total debt to equity
32.368
Interest coverage (TTM)
-4.05%
Profitability
EBITDA (TTM)
-123.794
Gross margin (TTM)
-50.31%
Net profit margin (TTM)
-87.14%
Operating margin (TTM)
-89.74%
Effective tax rate (TTM)
-1.33%
Revenue per employee (TTM)
$600,000
Management effectiveness
Return on assets (TTM)
-9.09%
Return on equity (TTM)
-19.56%
Valuation
Price to revenue (TTM)
6.842
Price to book
1.59
Price to tangible book (TTM)
1.61
Price to free cash flow (TTM)
-7.447
Free cash flow yield (TTM)
-13.43%
Free cash flow per share (TTM)
-1.867
Growth
Revenue change (TTM)
38.16%
Earnings per share change (TTM)
-48.57%
3-year revenue growth (CAGR)
-20.34%
10-year revenue growth (CAGR)
29.10%
3-year earnings per share growth (CAGR)
52.19%
10-year earnings per share growth (CAGR)
9.31%
What the Analysts think about Xencor
Analyst ratings (Buy, Hold, Sell) for Xencor stock.
Bulls say / Bears say
Xencor’s Q2 2025 revenue jumped 82% year-over-year to $43.6 million, driven by milestone payments from Incyte and royalties from Alexion. This underscores strong performance in its collaborations (Nasdaq).
As of June 30, 2025, Xencor had $663.8 million in cash, cash equivalents, and marketable securities, giving the company projected funding through 2028 and reducing near-term financing risk (BioSpace).
The company began its Phase 2b XENITH-UC study of XmAb942 for ulcerative colitis and received regulatory clearance to start a Phase 1b/2a plamotamab trial in rheumatoid arthritis in June 2025, showing progress across its oncology and autoimmune pipeline (BioSpace).
Xencor reported a net loss of $30.8 million in Q2 2025, showing it remains unprofitable even with revenue growth (Business Wire).
Research and development expenses were still high at $61.7 million in Q2 2025, reflecting a substantial cash burn that pressures margins and cash reserves (Business Wire).
Xencor is facing patent litigation from Merus N.V., which sued in August 2024 alleging infringement of three patents. This creates a risk of injunctions or damages that could hinder commercialization efforts (SEC).
Data summarised monthly by Lightyear AI. Last updated on 7 Nov 2025.
Xencor Financial Performance
Revenues and expenses
Xencor Earnings Performance
Company profitability
Xencor News
AllArticlesVideos
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma
Business Wire2 weeks ago
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Business Wire3 weeks ago
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xencor stock?
Xencor (XNCR) has a market cap of $993M as of November 10, 2025.
What is the P/E ratio for Xencor stock?
The price to earnings (P/E) ratio for Xencor (XNCR) stock is 0 as of November 10, 2025.
Does Xencor stock pay dividends?
No, Xencor (XNCR) stock does not pay dividends to its shareholders as of November 10, 2025.
When is the next Xencor dividend payment date?
Xencor (XNCR) stock does not pay dividends to its shareholders.
What is the beta indicator for Xencor?
Xencor (XNCR) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.